Researchers have reported preclinical evidence that repurposed, clinically available drugs may improve outcomes in KMT2A::AFF1 positive infant B-cell precursor acute lymphoblastic leukemia (BCP-ALL), a rare and rapidly progressing subtype in infants under one. The study focuses on targeting vulnerabilities tied to the KMT2A::AFF1 fusion and frames the approach as a potential fast-track route to expanded treatment options for a high-need pediatric population. The work is preclinical, but the authors emphasize that using already approved or clinically tested compounds could shorten the path to clinical evaluation compared with de novo discovery. If the signals hold up, the strategy could widen therapeutic options for clinicians facing limited effective choices for this aggressive disease biology.